CONCLUSION AND RESULTS
During the 2 years of treatment with baricitinib, the VAS itching score
had steadily decreased (Figure 2), and the patient reported significant
improvement in itching and sleep quality after treatment, without any
adverse effects. After discontinuation of baricitinib for 2 weeks, in
July 2022, the patient returned to the clinic for reexamination, and the
results indicated that the number of skin rashes on the outer side of
both thighs had decreased by half, and the color had become dull,
although some dark brown hyperpigmentation and scars remained on the
extensor aspect of both lower legs. (Figure 1E and 1F). The results of
regular reexaminations showed routine blood and urine with normal liver
and kidney function and electrolytes. Currently, the patient is still
under follow-up.